Your browser doesn't support javascript.
loading
The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination.
Seddiki, Nabila; Picard, Florence; Dupaty, Léa; Lévy, Yves; Godot, Véronique.
Afiliação
  • Seddiki N; Inserm, U955, Equipe 16, 94000 Créteil, France.
  • Picard F; Faculté de médecine, Université Paris Est, 94000 Créteil, France.
  • Dupaty L; Vaccine Research Institute (VRI), 94000 Créteil, France.
  • Lévy Y; INSERM U955 Equipe 16, Université Paris-Est Créteil, Vaccine Research Institute (VRI), 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France.
  • Godot V; Inserm, U955, Equipe 16, 94000 Créteil, France.
Vaccines (Basel) ; 8(3)2020 Jul 27.
Article em En | MEDLINE | ID: mdl-32726934
ABSTRACT
We discuss here some of the key immunological elements that are at the crossroads and need to be combined to develop a potent therapeutic HIV-1 vaccine. Therapeutic vaccines have been commonly used to enhance and/or recall pre-existing HIV-1-specific cell-mediated immune responses aiming to suppress virus replication. The current success of immune checkpoint blockers in cancer therapy renders them very attractive to use in HIV-1 infected individuals with the objective to preserve the function of HIV-1-specific T cells from exhaustion and presumably target the persistent cellular reservoir. The major latest advances in our understanding of the mechanisms responsible for virus reactivation during therapy-suppressed individuals provide the scientific basis for future combinatorial therapeutic vaccine development.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article